Impact of Sirflox failure to meet primary end point, page-6

Yabster

Agree - in some ways you wouldnt expect sorting out liver secondaries to stop tumour elsewhere -

I havent seen the data yet - but PFS is presumably different to how long a patient lives and quality of life.  

Montgomery follows this stock closely and his blog may have something on it today

Based on the preliminary analysis just completed, the primary endpoint of the SIRFLOX study was not achieved. The preliminary analysis shows that adding SIR-Spheres® Y-90 resin microspheres to a current first-line systemic chemotherapy regimen for the treatment of non-resectable metastatic colorectal cancer (mCRC) does not result in a statistically significant improvement in the overall Progression-Free Survival (PFS). Overall PFS measures progression of existing tumours and/or the development of new tumours in any organ or body site.